nodes	percent_of_prediction	percent_of_DWPC	metapath
Betamethasone—Embolism venous—Doxorubicin—liver cancer	0.00349	0.00695	CcSEcCtD
Betamethasone—Blindness—Epirubicin—liver cancer	0.00344	0.00684	CcSEcCtD
Betamethasone—Dry skin—Sorafenib—liver cancer	0.00343	0.00682	CcSEcCtD
Betamethasone—Hypokalaemia—Sorafenib—liver cancer	0.0034	0.00677	CcSEcCtD
Betamethasone—Hypernatraemia—Doxorubicin—liver cancer	0.00335	0.00667	CcSEcCtD
Betamethasone—Skin hyperpigmentation—Epirubicin—liver cancer	0.0032	0.00637	CcSEcCtD
Betamethasone—Blindness—Doxorubicin—liver cancer	0.00318	0.00633	CcSEcCtD
Betamethasone—Optic neuritis—Epirubicin—liver cancer	0.0031	0.00616	CcSEcCtD
Betamethasone—Folliculitis—Epirubicin—liver cancer	0.00303	0.00603	CcSEcCtD
Betamethasone—Embolism—Epirubicin—liver cancer	0.00297	0.0059	CcSEcCtD
Betamethasone—Skin hyperpigmentation—Doxorubicin—liver cancer	0.00296	0.00589	CcSEcCtD
Betamethasone—Keratitis—Epirubicin—liver cancer	0.00294	0.00584	CcSEcCtD
Betamethasone—Weight decreased—Sorafenib—liver cancer	0.00292	0.00582	CcSEcCtD
Betamethasone—Optic neuritis—Doxorubicin—liver cancer	0.00286	0.0057	CcSEcCtD
Betamethasone—Acute coronary syndrome—Sorafenib—liver cancer	0.00284	0.00565	CcSEcCtD
Betamethasone—Myocardial infarction—Sorafenib—liver cancer	0.00283	0.00562	CcSEcCtD
Betamethasone—Neuropathy peripheral—Sorafenib—liver cancer	0.00283	0.00562	CcSEcCtD
Betamethasone—Folliculitis—Doxorubicin—liver cancer	0.0028	0.00558	CcSEcCtD
Betamethasone—Embolism—Doxorubicin—liver cancer	0.00274	0.00546	CcSEcCtD
Betamethasone—Keratitis—Doxorubicin—liver cancer	0.00272	0.00541	CcSEcCtD
Betamethasone—Hepatomegaly—Epirubicin—liver cancer	0.00269	0.00535	CcSEcCtD
Betamethasone—Blister—Epirubicin—liver cancer	0.00264	0.00526	CcSEcCtD
Betamethasone—Haemoglobin—Sorafenib—liver cancer	0.0026	0.00518	CcSEcCtD
Betamethasone—Haemorrhage—Sorafenib—liver cancer	0.00259	0.00515	CcSEcCtD
Betamethasone—Neuritis—Epirubicin—liver cancer	0.00255	0.00508	CcSEcCtD
Betamethasone—Hepatomegaly—Doxorubicin—liver cancer	0.00249	0.00495	CcSEcCtD
Betamethasone—Rash erythematous—Epirubicin—liver cancer	0.00249	0.00495	CcSEcCtD
Betamethasone—Fungal infection—Epirubicin—liver cancer	0.00247	0.00491	CcSEcCtD
Betamethasone—Blister—Doxorubicin—liver cancer	0.00244	0.00486	CcSEcCtD
Betamethasone—Necrosis—Epirubicin—liver cancer	0.00243	0.00483	CcSEcCtD
Betamethasone—Abscess—Epirubicin—liver cancer	0.00241	0.00479	CcSEcCtD
Betamethasone—Neuritis—Doxorubicin—liver cancer	0.00236	0.0047	CcSEcCtD
Betamethasone—Stinging—Epirubicin—liver cancer	0.00235	0.00468	CcSEcCtD
Betamethasone—Glycosuria—Epirubicin—liver cancer	0.00235	0.00468	CcSEcCtD
Betamethasone—Angiopathy—Sorafenib—liver cancer	0.00235	0.00467	CcSEcCtD
Betamethasone—Petechiae—Epirubicin—liver cancer	0.00231	0.00461	CcSEcCtD
Betamethasone—Arrhythmia—Sorafenib—liver cancer	0.00231	0.0046	CcSEcCtD
Betamethasone—Rash erythematous—Doxorubicin—liver cancer	0.0023	0.00458	CcSEcCtD
Betamethasone—Alopecia—Sorafenib—liver cancer	0.00229	0.00455	CcSEcCtD
Betamethasone—Fungal infection—Doxorubicin—liver cancer	0.00228	0.00454	CcSEcCtD
Betamethasone—Erythema—Sorafenib—liver cancer	0.00225	0.00448	CcSEcCtD
Betamethasone—Necrosis—Doxorubicin—liver cancer	0.00225	0.00447	CcSEcCtD
Betamethasone—Abscess—Doxorubicin—liver cancer	0.00223	0.00443	CcSEcCtD
Betamethasone—Extravasation—Epirubicin—liver cancer	0.00218	0.00434	CcSEcCtD
Betamethasone—Glycosuria—Doxorubicin—liver cancer	0.00218	0.00433	CcSEcCtD
Betamethasone—Stinging—Doxorubicin—liver cancer	0.00218	0.00433	CcSEcCtD
Betamethasone—Amenorrhoea—Epirubicin—liver cancer	0.00217	0.00431	CcSEcCtD
Betamethasone—Petechiae—Doxorubicin—liver cancer	0.00214	0.00426	CcSEcCtD
Betamethasone—Arthropathy—Epirubicin—liver cancer	0.00209	0.00417	CcSEcCtD
Betamethasone—Herpes simplex—Epirubicin—liver cancer	0.00207	0.00411	CcSEcCtD
Betamethasone—Angioedema—Sorafenib—liver cancer	0.00206	0.0041	CcSEcCtD
Betamethasone—Syncope—Sorafenib—liver cancer	0.00202	0.00402	CcSEcCtD
Betamethasone—Extravasation—Doxorubicin—liver cancer	0.00202	0.00402	CcSEcCtD
Betamethasone—Ulcer—Epirubicin—liver cancer	0.00201	0.00401	CcSEcCtD
Betamethasone—Amenorrhoea—Doxorubicin—liver cancer	0.00201	0.00399	CcSEcCtD
Betamethasone—Loss of consciousness—Sorafenib—liver cancer	0.00198	0.00394	CcSEcCtD
Betamethasone—Hypertension—Sorafenib—liver cancer	0.00194	0.00387	CcSEcCtD
Betamethasone—Arthropathy—Doxorubicin—liver cancer	0.00194	0.00386	CcSEcCtD
Betamethasone—Myalgia—Sorafenib—liver cancer	0.00192	0.00382	CcSEcCtD
Betamethasone—Herpes simplex—Doxorubicin—liver cancer	0.00191	0.0038	CcSEcCtD
Betamethasone—Hiccups—Epirubicin—liver cancer	0.0019	0.00379	CcSEcCtD
Betamethasone—Dermatitis contact—Epirubicin—liver cancer	0.00188	0.00374	CcSEcCtD
Betamethasone—Ulcer—Doxorubicin—liver cancer	0.00186	0.00371	CcSEcCtD
Betamethasone—Anaphylactic shock—Sorafenib—liver cancer	0.00184	0.00366	CcSEcCtD
Betamethasone—Infection—Sorafenib—liver cancer	0.00183	0.00363	CcSEcCtD
Betamethasone—Skin exfoliation—Epirubicin—liver cancer	0.00182	0.00362	CcSEcCtD
Betamethasone—Shock—Sorafenib—liver cancer	0.00181	0.0036	CcSEcCtD
Betamethasone—Fluid retention—Epirubicin—liver cancer	0.00181	0.0036	CcSEcCtD
Betamethasone—Nervous system disorder—Sorafenib—liver cancer	0.0018	0.00359	CcSEcCtD
Betamethasone—Thrombocytopenia—Sorafenib—liver cancer	0.0018	0.00358	CcSEcCtD
Betamethasone—Neuropathy—Epirubicin—liver cancer	0.00179	0.00356	CcSEcCtD
Betamethasone—Hiccups—Doxorubicin—liver cancer	0.00176	0.00351	CcSEcCtD
Betamethasone—Dry eye—Epirubicin—liver cancer	0.00176	0.0035	CcSEcCtD
Betamethasone—Anorexia—Sorafenib—liver cancer	0.00175	0.00349	CcSEcCtD
Betamethasone—Dermatitis contact—Doxorubicin—liver cancer	0.00174	0.00347	CcSEcCtD
Betamethasone—Oesophagitis—Epirubicin—liver cancer	0.00174	0.00346	CcSEcCtD
Betamethasone—Ecchymosis—Epirubicin—liver cancer	0.00172	0.00343	CcSEcCtD
Betamethasone—Pulmonary oedema—Epirubicin—liver cancer	0.0017	0.00337	CcSEcCtD
Betamethasone—Skin exfoliation—Doxorubicin—liver cancer	0.00168	0.00335	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00167	0.00333	CcSEcCtD
Betamethasone—Fluid retention—Doxorubicin—liver cancer	0.00167	0.00333	CcSEcCtD
Betamethasone—Neuropathy—Doxorubicin—liver cancer	0.00165	0.00329	CcSEcCtD
Betamethasone—Dry eye—Doxorubicin—liver cancer	0.00163	0.00324	CcSEcCtD
Betamethasone—Dyspepsia—Sorafenib—liver cancer	0.00162	0.00322	CcSEcCtD
Betamethasone—Oesophagitis—Doxorubicin—liver cancer	0.00161	0.0032	CcSEcCtD
Betamethasone—Decreased appetite—Sorafenib—liver cancer	0.0016	0.00318	CcSEcCtD
Betamethasone—Thrombophlebitis—Epirubicin—liver cancer	0.0016	0.00318	CcSEcCtD
Betamethasone—Ecchymosis—Doxorubicin—liver cancer	0.00159	0.00317	CcSEcCtD
Betamethasone—Diabetes mellitus—Epirubicin—liver cancer	0.00159	0.00316	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Sorafenib—liver cancer	0.00159	0.00316	CcSEcCtD
Betamethasone—Fatigue—Sorafenib—liver cancer	0.00159	0.00315	CcSEcCtD
Betamethasone—Pain—Sorafenib—liver cancer	0.00157	0.00313	CcSEcCtD
Betamethasone—Pulmonary oedema—Doxorubicin—liver cancer	0.00157	0.00312	CcSEcCtD
Betamethasone—Eye pain—Epirubicin—liver cancer	0.00153	0.00305	CcSEcCtD
Betamethasone—Cardiac failure congestive—Epirubicin—liver cancer	0.00152	0.00303	CcSEcCtD
Betamethasone—Gastrointestinal pain—Sorafenib—liver cancer	0.0015	0.00299	CcSEcCtD
Betamethasone—Thrombophlebitis—Doxorubicin—liver cancer	0.00148	0.00294	CcSEcCtD
Betamethasone—Increased appetite—Epirubicin—liver cancer	0.00147	0.00293	CcSEcCtD
Betamethasone—Diabetes mellitus—Doxorubicin—liver cancer	0.00147	0.00293	CcSEcCtD
Betamethasone—Urticaria—Sorafenib—liver cancer	0.00146	0.00291	CcSEcCtD
Betamethasone—Abdominal pain—Sorafenib—liver cancer	0.00145	0.00289	CcSEcCtD
Betamethasone—Body temperature increased—Sorafenib—liver cancer	0.00145	0.00289	CcSEcCtD
Betamethasone—Dermatitis bullous—Epirubicin—liver cancer	0.00145	0.00288	CcSEcCtD
Betamethasone—Anaphylactoid reaction—Epirubicin—liver cancer	0.00143	0.00284	CcSEcCtD
Betamethasone—Eye pain—Doxorubicin—liver cancer	0.00142	0.00282	CcSEcCtD
Betamethasone—Cardiac failure—Epirubicin—liver cancer	0.00142	0.00282	CcSEcCtD
Betamethasone—Lethargy—Epirubicin—liver cancer	0.00141	0.00281	CcSEcCtD
Betamethasone—Cardiac failure congestive—Doxorubicin—liver cancer	0.00141	0.00281	CcSEcCtD
Betamethasone—Osteoarthritis—Epirubicin—liver cancer	0.00138	0.00275	CcSEcCtD
Betamethasone—Increased appetite—Doxorubicin—liver cancer	0.00136	0.00271	CcSEcCtD
Betamethasone—Migraine—Epirubicin—liver cancer	0.00136	0.00271	CcSEcCtD
Betamethasone—Affect lability—Epirubicin—liver cancer	0.00136	0.00271	CcSEcCtD
Betamethasone—Dermatitis bullous—Doxorubicin—liver cancer	0.00134	0.00266	CcSEcCtD
Betamethasone—Anaphylactoid reaction—Doxorubicin—liver cancer	0.00132	0.00263	CcSEcCtD
Betamethasone—Asthenia—Sorafenib—liver cancer	0.00132	0.00262	CcSEcCtD
Betamethasone—Cardiac arrest—Epirubicin—liver cancer	0.00131	0.00262	CcSEcCtD
Betamethasone—Cardiac failure—Doxorubicin—liver cancer	0.00131	0.00261	CcSEcCtD
Betamethasone—Mood swings—Epirubicin—liver cancer	0.00131	0.00261	CcSEcCtD
Betamethasone—Lethargy—Doxorubicin—liver cancer	0.00131	0.0026	CcSEcCtD
Betamethasone—Pruritus—Sorafenib—liver cancer	0.0013	0.00259	CcSEcCtD
Betamethasone—Osteoarthritis—Doxorubicin—liver cancer	0.00128	0.00255	CcSEcCtD
Betamethasone—Dry skin—Epirubicin—liver cancer	0.00127	0.00252	CcSEcCtD
Betamethasone—Affect lability—Doxorubicin—liver cancer	0.00126	0.00251	CcSEcCtD
Betamethasone—Migraine—Doxorubicin—liver cancer	0.00126	0.00251	CcSEcCtD
Betamethasone—Hypokalaemia—Epirubicin—liver cancer	0.00126	0.0025	CcSEcCtD
Betamethasone—Diarrhoea—Sorafenib—liver cancer	0.00126	0.0025	CcSEcCtD
Betamethasone—Muscular weakness—Epirubicin—liver cancer	0.00122	0.00243	CcSEcCtD
Betamethasone—Cardiac arrest—Doxorubicin—liver cancer	0.00122	0.00242	CcSEcCtD
Betamethasone—Dizziness—Sorafenib—liver cancer	0.00122	0.00242	CcSEcCtD
Betamethasone—Mood swings—Doxorubicin—liver cancer	0.00121	0.00241	CcSEcCtD
Betamethasone—Dry skin—Doxorubicin—liver cancer	0.00117	0.00233	CcSEcCtD
Betamethasone—Vomiting—Sorafenib—liver cancer	0.00117	0.00233	CcSEcCtD
Betamethasone—Hypokalaemia—Doxorubicin—liver cancer	0.00116	0.00232	CcSEcCtD
Betamethasone—Rash—Sorafenib—liver cancer	0.00116	0.00231	CcSEcCtD
Betamethasone—Dermatitis—Sorafenib—liver cancer	0.00116	0.0023	CcSEcCtD
Betamethasone—Headache—Sorafenib—liver cancer	0.00115	0.00229	CcSEcCtD
Betamethasone—Muscular weakness—Doxorubicin—liver cancer	0.00113	0.00224	CcSEcCtD
Betamethasone—Nausea—Sorafenib—liver cancer	0.00109	0.00217	CcSEcCtD
Betamethasone—Weight increased—Epirubicin—liver cancer	0.00109	0.00216	CcSEcCtD
Betamethasone—Weight decreased—Epirubicin—liver cancer	0.00108	0.00215	CcSEcCtD
Betamethasone—Hyperglycaemia—Epirubicin—liver cancer	0.00108	0.00214	CcSEcCtD
Betamethasone—Neuropathy peripheral—Epirubicin—liver cancer	0.00104	0.00208	CcSEcCtD
Betamethasone—Conjunctivitis—Epirubicin—liver cancer	0.00104	0.00206	CcSEcCtD
Betamethasone—Weight increased—Doxorubicin—liver cancer	0.00101	0.002	CcSEcCtD
Betamethasone—Weight decreased—Doxorubicin—liver cancer	0.001	0.00199	CcSEcCtD
Betamethasone—Hyperglycaemia—Doxorubicin—liver cancer	0.000997	0.00198	CcSEcCtD
Betamethasone—Bradycardia—Epirubicin—liver cancer	0.000974	0.00194	CcSEcCtD
Betamethasone—Neuropathy peripheral—Doxorubicin—liver cancer	0.000966	0.00192	CcSEcCtD
Betamethasone—Haemoglobin—Epirubicin—liver cancer	0.000961	0.00191	CcSEcCtD
Betamethasone—Conjunctivitis—Doxorubicin—liver cancer	0.000958	0.00191	CcSEcCtD
Betamethasone—Haemorrhage—Epirubicin—liver cancer	0.000956	0.0019	CcSEcCtD
Betamethasone—Visual impairment—Epirubicin—liver cancer	0.000922	0.00183	CcSEcCtD
Betamethasone—Bradycardia—Doxorubicin—liver cancer	0.000901	0.00179	CcSEcCtD
Betamethasone—Eye disorder—Epirubicin—liver cancer	0.000894	0.00178	CcSEcCtD
Betamethasone—Haemoglobin—Doxorubicin—liver cancer	0.000889	0.00177	CcSEcCtD
Betamethasone—Haemorrhage—Doxorubicin—liver cancer	0.000885	0.00176	CcSEcCtD
Betamethasone—Angiopathy—Epirubicin—liver cancer	0.000868	0.00173	CcSEcCtD
Betamethasone—Arrhythmia—Epirubicin—liver cancer	0.000854	0.0017	CcSEcCtD
Betamethasone—Visual impairment—Doxorubicin—liver cancer	0.000853	0.0017	CcSEcCtD
Betamethasone—Alopecia—Epirubicin—liver cancer	0.000845	0.00168	CcSEcCtD
Betamethasone—Erythema—Epirubicin—liver cancer	0.000833	0.00166	CcSEcCtD
Betamethasone—Eye disorder—Doxorubicin—liver cancer	0.000827	0.00165	CcSEcCtD
Betamethasone—Angiopathy—Doxorubicin—liver cancer	0.000803	0.0016	CcSEcCtD
Betamethasone—Arrhythmia—Doxorubicin—liver cancer	0.00079	0.00157	CcSEcCtD
Betamethasone—Alopecia—Doxorubicin—liver cancer	0.000782	0.00156	CcSEcCtD
Betamethasone—Ill-defined disorder—Epirubicin—liver cancer	0.000772	0.00154	CcSEcCtD
Betamethasone—Erythema—Doxorubicin—liver cancer	0.00077	0.00153	CcSEcCtD
Betamethasone—Malaise—Epirubicin—liver cancer	0.000751	0.00149	CcSEcCtD
Betamethasone—Vertigo—Epirubicin—liver cancer	0.000748	0.00149	CcSEcCtD
Betamethasone—Syncope—Epirubicin—liver cancer	0.000747	0.00149	CcSEcCtD
Betamethasone—Fluoxymesterone—ESR1—liver cancer	0.000733	0.325	CrCbGaD
Betamethasone—Loss of consciousness—Epirubicin—liver cancer	0.000732	0.00146	CcSEcCtD
Betamethasone—Convulsion—Epirubicin—liver cancer	0.000721	0.00144	CcSEcCtD
Betamethasone—Hypertension—Epirubicin—liver cancer	0.000719	0.00143	CcSEcCtD
Betamethasone—Ill-defined disorder—Doxorubicin—liver cancer	0.000715	0.00142	CcSEcCtD
Betamethasone—Clobetasol propionate—CYP1A1—liver cancer	0.00071	0.314	CrCbGaD
Betamethasone—Myalgia—Epirubicin—liver cancer	0.000709	0.00141	CcSEcCtD
Betamethasone—Anxiety—Epirubicin—liver cancer	0.000706	0.00141	CcSEcCtD
Betamethasone—Discomfort—Epirubicin—liver cancer	0.0007	0.00139	CcSEcCtD
Betamethasone—Malaise—Doxorubicin—liver cancer	0.000695	0.00138	CcSEcCtD
Betamethasone—Vertigo—Doxorubicin—liver cancer	0.000692	0.00138	CcSEcCtD
Betamethasone—Syncope—Doxorubicin—liver cancer	0.000691	0.00137	CcSEcCtD
Betamethasone—Anaphylactic shock—Epirubicin—liver cancer	0.000679	0.00135	CcSEcCtD
Betamethasone—Oedema—Epirubicin—liver cancer	0.000679	0.00135	CcSEcCtD
Betamethasone—Loss of consciousness—Doxorubicin—liver cancer	0.000677	0.00135	CcSEcCtD
Betamethasone—Infection—Epirubicin—liver cancer	0.000675	0.00134	CcSEcCtD
Betamethasone—Shock—Epirubicin—liver cancer	0.000668	0.00133	CcSEcCtD
Betamethasone—Convulsion—Doxorubicin—liver cancer	0.000667	0.00133	CcSEcCtD
Betamethasone—Nervous system disorder—Epirubicin—liver cancer	0.000666	0.00133	CcSEcCtD
Betamethasone—Thrombocytopenia—Epirubicin—liver cancer	0.000665	0.00132	CcSEcCtD
Betamethasone—Hypertension—Doxorubicin—liver cancer	0.000665	0.00132	CcSEcCtD
Betamethasone—Tachycardia—Epirubicin—liver cancer	0.000663	0.00132	CcSEcCtD
Betamethasone—Hyperhidrosis—Epirubicin—liver cancer	0.000657	0.00131	CcSEcCtD
Betamethasone—Myalgia—Doxorubicin—liver cancer	0.000656	0.0013	CcSEcCtD
Betamethasone—Anxiety—Doxorubicin—liver cancer	0.000654	0.0013	CcSEcCtD
Betamethasone—Discomfort—Doxorubicin—liver cancer	0.000648	0.00129	CcSEcCtD
Betamethasone—Anorexia—Epirubicin—liver cancer	0.000648	0.00129	CcSEcCtD
Betamethasone—Hypotension—Epirubicin—liver cancer	0.000635	0.00126	CcSEcCtD
Betamethasone—Oedema—Doxorubicin—liver cancer	0.000629	0.00125	CcSEcCtD
Betamethasone—Anaphylactic shock—Doxorubicin—liver cancer	0.000629	0.00125	CcSEcCtD
Betamethasone—Infection—Doxorubicin—liver cancer	0.000625	0.00124	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000619	0.00123	CcSEcCtD
Betamethasone—Shock—Doxorubicin—liver cancer	0.000619	0.00123	CcSEcCtD
Betamethasone—Nervous system disorder—Doxorubicin—liver cancer	0.000617	0.00123	CcSEcCtD
Betamethasone—Thrombocytopenia—Doxorubicin—liver cancer	0.000616	0.00122	CcSEcCtD
Betamethasone—Insomnia—Epirubicin—liver cancer	0.000615	0.00122	CcSEcCtD
Betamethasone—Tachycardia—Doxorubicin—liver cancer	0.000614	0.00122	CcSEcCtD
Betamethasone—Paraesthesia—Epirubicin—liver cancer	0.00061	0.00121	CcSEcCtD
Betamethasone—Hyperhidrosis—Doxorubicin—liver cancer	0.000608	0.00121	CcSEcCtD
Betamethasone—Anorexia—Doxorubicin—liver cancer	0.000599	0.00119	CcSEcCtD
Betamethasone—Dyspepsia—Epirubicin—liver cancer	0.000598	0.00119	CcSEcCtD
Betamethasone—Decreased appetite—Epirubicin—liver cancer	0.000591	0.00118	CcSEcCtD
Betamethasone—Hypotension—Doxorubicin—liver cancer	0.000587	0.00117	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Epirubicin—liver cancer	0.000587	0.00117	CcSEcCtD
Betamethasone—Fatigue—Epirubicin—liver cancer	0.000586	0.00117	CcSEcCtD
Betamethasone—Pain—Epirubicin—liver cancer	0.000581	0.00116	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000573	0.00114	CcSEcCtD
Betamethasone—Insomnia—Doxorubicin—liver cancer	0.000569	0.00113	CcSEcCtD
Betamethasone—Paraesthesia—Doxorubicin—liver cancer	0.000565	0.00112	CcSEcCtD
Betamethasone—Feeling abnormal—Epirubicin—liver cancer	0.00056	0.00111	CcSEcCtD
Betamethasone—Gastrointestinal pain—Epirubicin—liver cancer	0.000556	0.00111	CcSEcCtD
Betamethasone—Dyspepsia—Doxorubicin—liver cancer	0.000553	0.0011	CcSEcCtD
Betamethasone—Decreased appetite—Doxorubicin—liver cancer	0.000546	0.00109	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000543	0.00108	CcSEcCtD
Betamethasone—Fatigue—Doxorubicin—liver cancer	0.000542	0.00108	CcSEcCtD
Betamethasone—Urticaria—Epirubicin—liver cancer	0.00054	0.00107	CcSEcCtD
Betamethasone—Pain—Doxorubicin—liver cancer	0.000538	0.00107	CcSEcCtD
Betamethasone—Abdominal pain—Epirubicin—liver cancer	0.000537	0.00107	CcSEcCtD
Betamethasone—Body temperature increased—Epirubicin—liver cancer	0.000537	0.00107	CcSEcCtD
Betamethasone—Feeling abnormal—Doxorubicin—liver cancer	0.000518	0.00103	CcSEcCtD
Betamethasone—Gastrointestinal pain—Doxorubicin—liver cancer	0.000514	0.00102	CcSEcCtD
Betamethasone—Urticaria—Doxorubicin—liver cancer	0.000499	0.000994	CcSEcCtD
Betamethasone—Abdominal pain—Doxorubicin—liver cancer	0.000497	0.000989	CcSEcCtD
Betamethasone—Body temperature increased—Doxorubicin—liver cancer	0.000497	0.000989	CcSEcCtD
Betamethasone—Asthenia—Epirubicin—liver cancer	0.000487	0.00097	CcSEcCtD
Betamethasone—Pruritus—Epirubicin—liver cancer	0.000481	0.000957	CcSEcCtD
Betamethasone—Diarrhoea—Epirubicin—liver cancer	0.000465	0.000925	CcSEcCtD
Betamethasone—Asthenia—Doxorubicin—liver cancer	0.000451	0.000898	CcSEcCtD
Betamethasone—Dizziness—Epirubicin—liver cancer	0.000449	0.000894	CcSEcCtD
Betamethasone—Pruritus—Doxorubicin—liver cancer	0.000445	0.000885	CcSEcCtD
Betamethasone—Vomiting—Epirubicin—liver cancer	0.000432	0.00086	CcSEcCtD
Betamethasone—Diarrhoea—Doxorubicin—liver cancer	0.00043	0.000856	CcSEcCtD
Betamethasone—Rash—Epirubicin—liver cancer	0.000428	0.000852	CcSEcCtD
Betamethasone—Dermatitis—Epirubicin—liver cancer	0.000428	0.000852	CcSEcCtD
Betamethasone—Headache—Epirubicin—liver cancer	0.000426	0.000847	CcSEcCtD
Betamethasone—Dizziness—Doxorubicin—liver cancer	0.000416	0.000827	CcSEcCtD
Betamethasone—Nausea—Epirubicin—liver cancer	0.000404	0.000803	CcSEcCtD
Betamethasone—Vomiting—Doxorubicin—liver cancer	0.0004	0.000795	CcSEcCtD
Betamethasone—Rash—Doxorubicin—liver cancer	0.000396	0.000789	CcSEcCtD
Betamethasone—Dermatitis—Doxorubicin—liver cancer	0.000396	0.000788	CcSEcCtD
Betamethasone—Headache—Doxorubicin—liver cancer	0.000394	0.000784	CcSEcCtD
Betamethasone—Nausea—Doxorubicin—liver cancer	0.000373	0.000743	CcSEcCtD
Betamethasone—Prednisone—ALB—liver cancer	0.000282	0.125	CrCbGaD
Betamethasone—Dexamethasone—CYP2E1—liver cancer	0.000269	0.119	CrCbGaD
Betamethasone—Dexamethasone—CYP1A1—liver cancer	0.000266	0.118	CrCbGaD
Betamethasone—PTGS2—Metabolism—GLUL—liver cancer	0.000143	0.000289	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	0.000142	0.000287	CbGpPWpGaD
Betamethasone—PGR—Generic Transcription Pathway—MYC—liver cancer	0.000142	0.000287	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—PSMD10—liver cancer	0.00014	0.000282	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—PSMA4—liver cancer	0.00014	0.000282	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—IL6—liver cancer	0.000139	0.00028	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—HPGDS—liver cancer	0.000138	0.000279	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—NR1H4—liver cancer	0.000138	0.000279	CbGpPWpGaD
Betamethasone—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.000138	0.000279	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—liver cancer	0.000137	0.000277	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	0.000136	0.000275	CbGpPWpGaD
Betamethasone—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.000136	0.000275	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GSTA3—liver cancer	0.000136	0.000274	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—MAPK14—liver cancer	0.000134	0.000271	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—PIK3CB—liver cancer	0.000133	0.000269	CbGpPWpGaD
Betamethasone—PTGS2—Disease—ALDOB—liver cancer	0.000132	0.000267	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—ESR1—liver cancer	0.000132	0.000266	CbGpPWpGaD
Betamethasone—NR3C1—Generic Transcription Pathway—SERPINE1—liver cancer	0.00013	0.000262	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	0.000127	0.000256	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	0.000125	0.000253	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	0.000125	0.000253	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	0.000125	0.000253	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GSTA4—liver cancer	0.000124	0.000251	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—ALB—liver cancer	0.000124	0.000249	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PSMA4—liver cancer	0.000123	0.000249	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PSMD10—liver cancer	0.000123	0.000249	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PRKCE—liver cancer	0.000122	0.000246	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	0.000121	0.000245	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GSTA2—liver cancer	0.000121	0.000245	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—PPARG—liver cancer	0.00012	0.000242	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—GOT2—liver cancer	0.00012	0.000242	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GSTA1—liver cancer	0.000117	0.000236	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	0.000117	0.000236	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	0.000116	0.000234	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	0.000116	0.000234	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—NAT2—liver cancer	0.000116	0.000233	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—IGF2—liver cancer	0.000115	0.000233	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	0.000114	0.00023	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—CYP2E1—liver cancer	0.000113	0.000228	CbGpPWpGaD
Betamethasone—NR3C2—Gene Expression—MYC—liver cancer	0.000112	0.000227	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	0.000111	0.000224	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	0.000111	0.000224	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—ALDOB—liver cancer	0.000111	0.000224	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	0.000111	0.000223	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	0.00011	0.000222	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	0.000109	0.00022	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—SERPINE1—liver cancer	0.000108	0.000218	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CSF2—liver cancer	0.000108	0.000217	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	0.000107	0.000216	CbGpPWpGaD
Betamethasone—ABCB1—Transmembrane transport of small molecules—CYCS—liver cancer	0.000107	0.000215	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	0.000106	0.000215	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—H2AFX—liver cancer	0.000106	0.000214	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CRABP1—liver cancer	0.000106	0.000213	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—CYCS—liver cancer	0.000105	0.000213	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	0.000105	0.000211	CbGpPWpGaD
Betamethasone—PTGS2—Disease—ADAM17—liver cancer	0.000105	0.000211	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—GGT1—liver cancer	0.000103	0.000209	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—GOT1—liver cancer	0.000103	0.000209	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—UGDH—liver cancer	0.000103	0.000209	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	0.000103	0.000208	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CPT1B—liver cancer	0.000102	0.000205	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GLUL—liver cancer	0.000102	0.000205	CbGpPWpGaD
Betamethasone—PTGS2—Disease—PSMA4—liver cancer	9.83e-05	0.000198	CbGpPWpGaD
Betamethasone—PTGS2—Disease—PSMD10—liver cancer	9.83e-05	0.000198	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—NR1H4—liver cancer	9.8e-05	0.000198	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—EPT1—liver cancer	9.71e-05	0.000196	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	9.66e-05	0.000195	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GSTA3—liver cancer	9.63e-05	0.000194	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—TERT—liver cancer	9.6e-05	0.000194	CbGpPWpGaD
Betamethasone—PTGS2—Disease—GOT2—liver cancer	9.56e-05	0.000193	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	9.51e-05	0.000192	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—H2AFX—liver cancer	9.43e-05	0.000191	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—GSTP1—liver cancer	9.29e-05	0.000188	CbGpPWpGaD
Betamethasone—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	9.27e-05	0.000187	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—HPGDS—liver cancer	9.23e-05	0.000186	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—TAT—liver cancer	9.21e-05	0.000186	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	9.18e-05	0.000185	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—HMOX1—liver cancer	9.16e-05	0.000185	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	8.89e-05	0.000179	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	8.86e-05	0.000179	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GSTA4—liver cancer	8.81e-05	0.000178	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—KDR—liver cancer	8.78e-05	0.000177	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—MAPK14—liver cancer	8.72e-05	0.000176	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	8.69e-05	0.000176	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GSTA2—liver cancer	8.58e-05	0.000173	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—ESR1—liver cancer	8.55e-05	0.000173	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—GSTM1—liver cancer	8.54e-05	0.000172	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—F2—liver cancer	8.45e-05	0.000171	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—PPARA—liver cancer	8.39e-05	0.00017	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	8.36e-05	0.000169	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GSTA1—liver cancer	8.28e-05	0.000167	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	8.28e-05	0.000167	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—ALB—liver cancer	8.25e-05	0.000167	CbGpPWpGaD
Betamethasone—PTGS2—Disease—GOT1—liver cancer	8.25e-05	0.000167	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PSMA4—liver cancer	8.23e-05	0.000166	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PSMD10—liver cancer	8.23e-05	0.000166	CbGpPWpGaD
Betamethasone—NR3C1—Generic Transcription Pathway—MYC—liver cancer	8.22e-05	0.000166	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	8.21e-05	0.000166	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—NAT2—liver cancer	8.19e-05	0.000165	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—PIK3CA—liver cancer	8.11e-05	0.000164	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—CYP1A1—liver cancer	8.09e-05	0.000163	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—APC—liver cancer	8.09e-05	0.000163	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PIK3CG—liver cancer	8.09e-05	0.000163	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GOT2—liver cancer	8.01e-05	0.000162	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—ALDOB—liver cancer	7.85e-05	0.000159	CbGpPWpGaD
Betamethasone—NR3C2—Gene Expression—AKT1—liver cancer	7.79e-05	0.000157	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—MAPK14—liver cancer	7.75e-05	0.000157	CbGpPWpGaD
Betamethasone—PTGS2—Disease—PRKCE—liver cancer	7.61e-05	0.000154	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—ESR1—liver cancer	7.6e-05	0.000154	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—BRAF—liver cancer	7.6e-05	0.000153	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—MTHFR—liver cancer	7.55e-05	0.000152	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	7.54e-05	0.000152	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CYP2E1—liver cancer	7.53e-05	0.000152	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CRABP1—liver cancer	7.49e-05	0.000151	CbGpPWpGaD
Betamethasone—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	7.49e-05	0.000151	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PPARA—liver cancer	7.4e-05	0.000149	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	7.3e-05	0.000147	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	7.29e-05	0.000147	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PIK3CD—liver cancer	7.11e-05	0.000144	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CYCS—liver cancer	7.04e-05	0.000142	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—SERPINE1—liver cancer	7.03e-05	0.000142	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—PPARG—liver cancer	6.94e-05	0.00014	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GOT1—liver cancer	6.91e-05	0.00014	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GGT1—liver cancer	6.91e-05	0.00014	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—MYC—liver cancer	6.84e-05	0.000138	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.65e-05	0.000134	CbGpPWpGaD
Betamethasone—PTGS2—Disease—H2AFX—liver cancer	6.64e-05	0.000134	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—AKT1—liver cancer	6.62e-05	0.000134	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—HPGDS—liver cancer	6.55e-05	0.000132	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—RAF1—liver cancer	6.35e-05	0.000128	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PIK3CG—liver cancer	6.34e-05	0.000128	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GLUL—liver cancer	6.26e-05	0.000126	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CPT1B—liver cancer	6.26e-05	0.000126	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—SERPINE1—liver cancer	6.25e-05	0.000126	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GSTP1—liver cancer	6.21e-05	0.000125	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—MTOR—liver cancer	6.2e-05	0.000125	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PIK3CB—liver cancer	6.2e-05	0.000125	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	6.16e-05	0.000124	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—HMOX1—liver cancer	6.12e-05	0.000124	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PPARG—liver cancer	6.12e-05	0.000124	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—NR1H4—liver cancer	6.03e-05	0.000122	CbGpPWpGaD
Betamethasone—PTGS2—Disease—MTHFR—liver cancer	6.02e-05	0.000122	CbGpPWpGaD
Betamethasone—PTGS2—Disease—TERT—liver cancer	6e-05	0.000121	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GSTA3—liver cancer	5.93e-05	0.00012	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PSMD10—liver cancer	5.83e-05	0.000118	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PSMA4—liver cancer	5.83e-05	0.000118	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CDKN1B—liver cancer	5.81e-05	0.000117	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GSTM1—liver cancer	5.7e-05	0.000115	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CASP3—liver cancer	5.7e-05	0.000115	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—IL2—liver cancer	5.69e-05	0.000115	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GOT2—liver cancer	5.68e-05	0.000115	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PIK3CD—liver cancer	5.57e-05	0.000113	CbGpPWpGaD
Betamethasone—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	5.56e-05	0.000112	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CCND1—liver cancer	5.55e-05	0.000112	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—JUN—liver cancer	5.54e-05	0.000112	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—ALB—liver cancer	5.5e-05	0.000111	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CTNNB1—liver cancer	5.49e-05	0.000111	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GSTA4—liver cancer	5.43e-05	0.00011	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CYP1A1—liver cancer	5.41e-05	0.000109	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—MMP9—liver cancer	5.39e-05	0.000109	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CDKN1A—liver cancer	5.37e-05	0.000108	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CYP2E1—liver cancer	5.34e-05	0.000108	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GSTA2—liver cancer	5.29e-05	0.000107	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—MAPK8—liver cancer	5.24e-05	0.000106	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GSTA1—liver cancer	5.1e-05	0.000103	CbGpPWpGaD
Betamethasone—PTGS2—Disease—APC—liver cancer	5.06e-05	0.000102	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—NAT2—liver cancer	5.04e-05	0.000102	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—MTHFR—liver cancer	5.04e-05	0.000102	CbGpPWpGaD
Betamethasone—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	5.03e-05	0.000102	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CYCS—liver cancer	4.99e-05	0.000101	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PPARA—liver cancer	4.95e-05	9.99e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GGT1—liver cancer	4.9e-05	9.89e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GOT1—liver cancer	4.9e-05	9.89e-05	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PIK3CB—liver cancer	4.86e-05	9.81e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—ALDOB—liver cancer	4.84e-05	9.77e-05	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—VEGFA—liver cancer	4.84e-05	9.77e-05	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—STAT3—liver cancer	4.79e-05	9.67e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—BRAF—liver cancer	4.75e-05	9.6e-05	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—AKT1—liver cancer	4.75e-05	9.58e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CRABP1—liver cancer	4.61e-05	9.32e-05	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—MYC—liver cancer	4.45e-05	8.99e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—PIK3CD—liver cancer	4.45e-05	8.98e-05	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.44e-05	8.97e-05	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—TGFB1—liver cancer	4.44e-05	8.96e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GSTP1—liver cancer	4.4e-05	8.89e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—SERPINE1—liver cancer	4.4e-05	8.88e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—HMOX1—liver cancer	4.34e-05	8.76e-05	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PIK3CG—liver cancer	4.24e-05	8.55e-05	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—KRAS—liver cancer	4.11e-05	8.3e-05	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PPARG—liver cancer	4.09e-05	8.26e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GSTM1—liver cancer	4.04e-05	8.17e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—HPGDS—liver cancer	4.03e-05	8.14e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—RAF1—liver cancer	3.97e-05	8.02e-05	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—MYC—liver cancer	3.96e-05	7.99e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—PIK3CB—liver cancer	3.88e-05	7.83e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—MTOR—liver cancer	3.88e-05	7.83e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CYP1A1—liver cancer	3.83e-05	7.74e-05	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PIK3CA—liver cancer	3.78e-05	7.63e-05	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PIK3CD—liver cancer	3.72e-05	7.52e-05	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—ALB—liver cancer	3.68e-05	7.42e-05	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—TP53—liver cancer	3.65e-05	7.38e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—CDKN1B—liver cancer	3.64e-05	7.35e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PSMA4—liver cancer	3.59e-05	7.26e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PSMD10—liver cancer	3.59e-05	7.26e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—MTHFR—liver cancer	3.57e-05	7.22e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PPARA—liver cancer	3.51e-05	7.08e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GOT2—liver cancer	3.5e-05	7.06e-05	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—HRAS—liver cancer	3.49e-05	7.06e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—CTNNB1—liver cancer	3.44e-05	6.94e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—CDKN1A—liver cancer	3.36e-05	6.78e-05	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—IL6—liver cancer	3.34e-05	6.75e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CYP2E1—liver cancer	3.29e-05	6.64e-05	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PIK3CB—liver cancer	3.25e-05	6.55e-05	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—AKT1—liver cancer	3.09e-05	6.23e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CYCS—liver cancer	3.08e-05	6.21e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GGT1—liver cancer	3.02e-05	6.1e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GOT1—liver cancer	3.02e-05	6.1e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PIK3CG—liver cancer	3e-05	6.06e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—STAT3—liver cancer	3e-05	6.05e-05	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PIK3CA—liver cancer	2.96e-05	5.98e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PPARG—liver cancer	2.9e-05	5.85e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—MYC—liver cancer	2.78e-05	5.62e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—TGFB1—liver cancer	2.78e-05	5.61e-05	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—AKT1—liver cancer	2.74e-05	5.54e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GSTP1—liver cancer	2.71e-05	5.48e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—HMOX1—liver cancer	2.67e-05	5.4e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PIK3CD—liver cancer	2.64e-05	5.33e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—ALB—liver cancer	2.61e-05	5.26e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—KRAS—liver cancer	2.57e-05	5.19e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GSTM1—liver cancer	2.49e-05	5.03e-05	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—AKT1—liver cancer	2.42e-05	4.89e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—PIK3CA—liver cancer	2.36e-05	4.77e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CYP1A1—liver cancer	2.36e-05	4.77e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PIK3CB—liver cancer	2.3e-05	4.65e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—MTHFR—liver cancer	2.2e-05	4.45e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—HRAS—liver cancer	2.19e-05	4.41e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PPARA—liver cancer	2.16e-05	4.36e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—IL6—liver cancer	2.09e-05	4.23e-05	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PIK3CA—liver cancer	1.98e-05	4e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—AKT1—liver cancer	1.93e-05	3.9e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PIK3CG—liver cancer	1.85e-05	3.74e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PPARG—liver cancer	1.79e-05	3.61e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PIK3CD—liver cancer	1.63e-05	3.28e-05	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—AKT1—liver cancer	1.62e-05	3.26e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—ALB—liver cancer	1.61e-05	3.24e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PIK3CB—liver cancer	1.42e-05	2.86e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PIK3CA—liver cancer	1.4e-05	2.83e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—AKT1—liver cancer	1.15e-05	2.31e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PIK3CA—liver cancer	8.64e-06	1.75e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—AKT1—liver cancer	7.06e-06	1.43e-05	CbGpPWpGaD
